Griseofulvin and fluvoxamine interactions with the metabolism of theophylline

Therapeutic Drug Monitoring

Volumn 19, Issue 1, 1997, Pages 56-62

  Rasmussen, Birgitte Buur ^a   Jeppesen, Unni ^a   Gaist, David ^a   Brøsen, Kim ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

CYP1A2; Fluvoxamine; Griseofulvin; Interaction; Theophylline

Indexed keywords

CYTOCHROME P450; FLUVOXAMINE; GRISEOFULVIN; TEOFYLAMIN; THEOPHYLLINE; UNCLASSIFIED DRUG;

ADULT; ANTIFUNGAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; DNA POLYMORPHISM; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; GENETIC SUSCEPTIBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROXYLATION; LIVER METABOLISM; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; ANTIBIOTICS, ANTIFUNGAL; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP1A2; DRUG INTERACTIONS; FLUVOXAMINE; GRISEOFULVIN; HUMANS; MALE; SEROTONIN UPTAKE INHIBITORS; THEOPHYLLINE;

EID: 0031431835     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199702000-00010     Document Type: Article

References (41)

1. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23.
2. Campbell ME, Grant DM, Inaba T, Kalow W. Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos 1987;15:237-49.
3. Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF. Human cytochrome P-450PA (P-450IA2). the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 1989;86:7696-700.
4. Hiemke C, Weigmann H, Härtter S, Dahmen N, Wetzel H, Müller H. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994;14:279-81.
5. Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994;16:368-74.
6. Bertilsson L, Carrillo JA, Dahl M, et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994;38:471-3.
7. Shaw L, Lennard MS, Tucker GT, Bax ND, Woods HF. Irreversible binding and metabolism of propranolol by human liver microsomes: relationship to polymorphic oxidation. Biochem Pharmacol 1987;36:2283-8.
8. Masubuchi Y, Hosokawa S, Horie T, et al. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes: the role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos 1994;22:909-15.
9. Madden S, Woolf TF, Pool WF, Park BK. An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro: studies with human and rat liver microsomes. Biochem Pharmacol 1993;46:13-20.
10. Vistisen K, Poulsen HE, Loft S. Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine. Carcinogenesis 1992;13:1561-8.
11. Kalow W, Tang BK. Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking [Comments]. Clin Pharmacol Ther 1991;49:44-8.
12. Parsons WD, Neims AH. Effect of smoking on caffeine clearance. Clin Pharmacol Ther 1978;24:40-5.
13. Kappas A, Alvares AP, Anderson KE, et al. Effect of charcoal-broiled beef on antipyrine and theophylline metabolism. Clin Pharmacol Ther 1978;23:445-50.
14. Sinha R, Rothman N, Brown ED, et al. Pan-fried meat containing high levels of heterocyclic aromatic amines but low levels of polycyclic aromatic hydrocarbons induces cytochrome P4501A2 activity in humans. Cancer Res 1994;54:6154-9.
15. Abernethy DR, Todd EL. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol 1985;28:425-8.
16. Rietveld EC, Broekman MM, Houben JJ, Eskes TK, van Rossum JM. Rapid onset of an increase in caffeine residence time in young women due to oral contraceptive steroids. Eur J Clin Pharmacol 1984;26:371-3.
17. Rost KL, Brosicke H, Brockmoller J, Scheffler M, Helge H, Roots I. Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 1992;52:170-80.
18. Nousbaum JB, Berthou F, Carlhant D, Riche C, Robaszkiewicz M, Gouerou H. Four-week treatment with omeprazole increases the metabolism of caffeine. Am J Gastroenterol 1994;89:371-5.
19. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-4.
20. Sesardic D, Boobis AR, Murray BP, et al. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol 1990;29:651-63.
21. Ogilvie RI. Clinical pharmacokinetics of theophylline. Clin Pharmacokinet 1978;3:267-93.
22. Grygiel JJ, Wing LM, Farkas J, Birkett DJ. Effects of allopurinol on theophylline metabolism and clearance. Clin Pharmacol Ther 1979;26:660-7.
23. Robson RA, Miners JO, Matthews AP, et al. Characterisation of theophylline metabolism by human liver microsomes: inhibition and immunochemical studies. Biochem Pharmacol 1988;37: 1651-9.
24. Rasmussen BB, Maenpaa J, Pelkonen O, et al. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995;39:151-9.
25. Sarkar MA, Hunt C, Guzelian PS, Karnes HT. Characterization of human liver cytochromes P-450 involved in theophylline metabolism. Drug Metab Dispos 1992;20:31-7.
26. Jeppesen U, Loft S, Poulsen HE, Brosen K. A fluvoxamine-caffeine interaction study. Pharmacogenetics 1996;6:213-22.
27. Sperber AD. Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Saf 1991;6: 460-2.
28. Diot P, Jonville AP, Gerard F. et al. Possible interaction between theophylline and fluvoxamine. Therapie 1991;46:170-1.
29. Thomson AH, McGovern EM, Bennie P, Caldwell G, Smith M. Interaction between fluvoxamine and theophylline. The Pharmaceutical Journal 1992; August: 137
30. Puranik A, Fitzpatrick R, Ananthanarayanan TS. Monitor serum theophylline. Care of elderly 1993:237.
31. van den Brekel A, Harrington L. Toxic effects of theophylline caused by fluvoxamine. Can Med Assoc J 1994;151:1289-90.
32. Okino K, Weibert RT. Warfarin-griseofulvin interaction. Drug Intell Clin Pharm 1986;20:291-3.
33. van Dijke CP, Weber JC. Interaction between oral contraceptives and griseofulvin. Br Med J Clin Res Ed 1984;288:1125-6.
34. Cote J. Interaction of griseofulvin and oral contraceptives [Comments]. J Am Acad Dermatol 1990;22:124-5.
35. Phillips KR, Wideman SD, Cochran EB, Becker JA. Griseofulvin significantly decreases serum salicylate concentrations. Pediatr Infect Dis J 1993;12:350-2.
36. Penman BW, Chen L, Gelboin HV, Gonzalez FJ, Crespi CL. Development of a human lymphoblastoid cell line constitutively expressing human CYP1A1 cDNA: substrate specificity with model substrates and promutagens. Carcinogenesis 1994;15:1931-7.
37. Rasmussen BB, Brøsen K. Determination of theophylline and its metabolites in human urine and plasma by high-performance liquid chromatography. J Chromatogr B 1996;676:169-74.
38. Spina E, Campo GM, Avenoso A, Pollicino MA, Caputi AP. Interaction between fluvoxamine and imipramine/desipramine in four patients. Ther Drug Monit 1992;14:194-6.
39. Benfield P, Ward A. Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986;32:313-34.
40. Nebert DW. The Ah locus: genetic differences in toxicity, cancer, mutation, and birth defects. Crit Rev Toxicol 1989;20:153-74.
41. Nebert DW, Petersen DD, Puga A. Human AH locus polymorphism and cancer: inducibility of CYP1A1 and other genes by combustion products anddioxin. Pharmacogenetics 1991;1:68-78.